Literature DB >> 15801072

Intravenous immunoglobulin in treatment of cardiac tamponade in a patient with systemic lupus erythematosus.

Tal Grenader1, Linda Shavit.   

Abstract

We describe a 23-year-old female patient with a history of systemic lupus erythematosus and pulmonary hypertension who developed a large pericardial effusion with cardiac tamponade. Invasive interventions such as pericardial window or pericardiectomy were ruled out because of the posterior localization of the effusion and high risk of general anesthesia in a patient with severe pulmonary hypertension. The patient received high-dose steroids intravenously with no response. A 5-day course of intravenous immunoglobulin resulted in gradual decrease of the pericardial effusion and resolution of cardiac tamponade within 2 weeks.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15801072     DOI: 10.1007/s10067-004-0931-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

Review 1.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Authors:  M D Kazatchkine; S V Kaveri
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

2.  Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus.

Authors:  Y Sherer; Y Levy; Y Shoenfeld
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

Review 3.  Cardiac involvement in systemic lupus erythematosus.

Authors:  K G Moder; T D Miller; H D Tazelaar
Journal:  Mayo Clin Proc       Date:  1999-03       Impact factor: 7.616

4.  Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis.

Authors:  M Meissner; Y Sherer; Y Levy; H Chwalinska-Sadowska; P Langevitz; Y Shoenfeld
Journal:  Rheumatol Int       Date:  2000       Impact factor: 2.631

5.  Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin.

Authors:  Y Sherer; P Langevitz; Y Levy; F Fabrizzi; Y Shoenfeld
Journal:  Lupus       Date:  1999       Impact factor: 2.911

6.  A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response.

Authors:  Y Levy; Y Sherer; A Ahmed; P Langevitz; J George; F Fabbrizzi; J Terryberry; M Meissner; M Lorber; J B Peter; Y Shoenfeld
Journal:  Lupus       Date:  1999       Impact factor: 2.911

7.  Lupus refractory pleural effusion: transient response to intravenous immunoglobulins.

Authors:  E Ben-Chetrit; C Putterman; Y Naparstek
Journal:  J Rheumatol       Date:  1991-10       Impact factor: 4.666

Review 8.  Cardiovascular manifestations of systemic lupus erythematosus.

Authors:  N E Doherty; R J Siegel
Journal:  Am Heart J       Date:  1985-12       Impact factor: 4.749

  8 in total
  5 in total

Review 1.  Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Authors:  Gisele Zandman-Goddard; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  High-dose intravenous immunoglobulin in recurrent postpericardiotomy syndrome.

Authors:  G Wendelin; A Fandl; A Beitzke
Journal:  Pediatr Cardiol       Date:  2008-03       Impact factor: 1.655

Review 3.  Current and novel therapeutics in the treatment of systemic lupus erythematosus.

Authors:  Cagri Yildirim-Toruner; Betty Diamond
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

4.  Intravenous immunoglobulin therapy leading to dramatic improvement in a patient with systemic juvenile idiopathic arthritis and severe pericarditis resistant to steroid pulse therapy.

Authors:  Tomomi Aizawa-Yashiro; Eishin Oki; Kazushi Tsuruga; Tohru Nakahata; Etsuro Ito; Hiroshi Tanaka
Journal:  Rheumatol Int       Date:  2010-03-18       Impact factor: 2.631

Review 5.  Calcified constrictive pericarditis resulting in tamponade in a patient with systemic lupus erythematosus.

Authors:  Antigone Pieta; Eleftherios Pelechas; Nafsika Gerolymatou; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Rheumatol Int       Date:  2020-11-18       Impact factor: 2.631

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.